ITGAX and neoplasm: Further, to assess the change in the TME induced by BG34-200 treatment, we utilized a transgenic CD11c-venus mouse strain (B6.Cg-Tg(Itgax-Venus)1Mnz/J) to examine tumor-infiltrating CD11c+ DC frequency (Figure 4C, left).